RNA medicine is no longer an emerging science, it’s becoming one of the biggest growth stories in global biotechnology. Now, Perth-based Syngenis Labs is positioning itself to capitalise on that momentum as it prepares for an ASX listing.
The company sits at the intersection of several powerful investment themes. Genetic medicine, artificial intelligence and Australia’s push to build sovereign biotechnology capability. Backed by an oversubscribed $4 million pre-IPO raise, Syngenis is building the infrastructure needed to support what management believes will be the next wave of RNA-based therapeutics.
RNA medicine has entered the mainstream
The COVID-19 pandemic changed the way the world viewed RNA technology.
Messenger RNA (mRNA) vaccines demonstrated that genetic medicine could move from laboratory research to global commercial deployment at unprecedented speed. Since then, investment into RNA-based therapies has accelerated across cancer, neurological disorders, rare diseases and metabolic conditions.
Another rapidly expanding area is oligonucleotide therapies, short synthetic strands of genetic material designed to selectively target disease-causing genes. Rather than treating symptoms, these therapies aim to intervene at the genetic level, making them one of the most promising areas of modern medicine.
As more therapies advance through clinical development, demand is also increasing for specialist manufacturers capable of producing research and clinical-grade genetic materials.
That is where Syngenis is looking to establish its position.
An IPO backed by sophisticated investors
Investor interest has already been evident.
The company recently completed an oversubscribed $4 million pre-IPO capital raising, attracting sophisticated investors through Euroz Hartleys ahead of its planned ASX listing.
The capital will primarily fund construction of a Good Manufacturing Practice (GMP) facility in Perth, which is expected to become operational during the first quarter of 2027.
For investors, this facility is more than another laboratory.
It would allow Syngenis to manufacture clinical-grade oligonucleotides suitable for human trials, placing the business among a relatively small number of manufacturers capable of servicing this specialised market.
The facility is also expected to support production of advanced chemistries such as phosphorodiamidate morpholino oligomers (PMOs), products currently manufactured by only a limited number of companies globally.
Building a platform, not a single product
Unlike many biotechnology companies that rely on the success of one experimental drug, Syngenis has built its business around a broader technology platform.
Founded by internationally recognised oligonucleotide scientist Professor Rakesh Veedu, the business has evolved from a research service established at Murdoch University into an independent biotechnology company supplying custom DNA and RNA products across Australia, New Zealand and international markets.
Rather than betting on a single therapeutic program, Syngenis provides specialist design, synthesis and manufacturing services that can support multiple customers and multiple drug development programs simultaneously.
That diversified approach has the potential to create several revenue streams from one underlying technology platform, reducing reliance on any single clinical outcome.
Artificial intelligence joins the laboratory
Another pillar of the strategy is the company’s proprietary Discovery AI platform.
The platform is designed to streamline the early stages of drug development by identifying therapeutic targets, designing RNA and DNA candidates, screening potential molecules and preparing them for laboratory validation through a single integrated workflow.
By combining AI-driven discovery with in-house synthesis and future GMP manufacturing, Syngenis is aiming to shorten development timelines while keeping more of the value chain under one roof.
Management is also integrating six operating divisions into a unified platform ahead of its ASX debut, creating a business model that spans discovery, design, manufacturing and commercial supply.
Riding Australia’s sovereign biotech push
Australia’s experience during the pandemic highlighted the importance of domestic biotechnology capability.
Governments and industry have increasingly prioritised sovereign manufacturing, recognising the strategic value of local expertise in advanced medicines.
With planned GMP manufacturing, RNA expertise and proprietary AI technology, Syngenis is positioning itself within that broader shift toward locally developed biotechnology infrastructure.
The opportunity extends beyond one therapeutic program. The company is seeking exposure to several long-term growth themes simultaneously, including precision medicine, RNA therapeutics, artificial intelligence and sovereign biotech manufacturing.
As Syngenis moves closer to its ASX listing, investors will be watching for progress on its GMP facility, continued commercial expansion and the rollout of its integrated Discovery AI platform.
If execution matches ambition, the company could emerge as one of Australia’s most influential biotechnology listings in the years ahead.
